---
schema_version: "secwatch.filing_event.v1"
accession: "0001493152-22-028015"
form_type: "8-K"
ticker: "INBS"
cik: "0001725430"
company_name: "INTELLIGENT BIO SOLUTIONS INC."
filed_at: "2022-10-11T23:59:59+00:00"
generated_at: "2026-06-23T04:27:18.154576+00:00"
event_type: "m_and_a"
sentiment: "positive"
materiality_score: 0.85
calibrated_materiality_score: 0.85
confidence: "high"
source: SEC EDGAR
---

# GBS acquires Intelligent Fingerprinting for stock; expands non-invasive drug testing

## Summary
- Acquired IFP for 2,963,091 common shares + 2,363,003 Series C preferred; up to 1,649,273 additional preferred reserved.
- IFP's 10-min fingerprint sweat test detects opioids, cocaine, methamphetamines, benzodiazepines, marijuana; over 200 customers.
- Board increased to 7 members; Jason Isenberg and David Jenkins appointed as directors.
- Preferred shares convertible into 3 common shares, subject to shareholder approval; 12-month lock-up on issued shares.
- GBS to file TGA application for IFP's CE Mark in Australia; IFP's UK ISO 13485 facility complements GBS Australia facility.

## SEC filing metadata
- accession: 0001493152-22-028015
- form_type: 8-K
- ticker: INBS
- cik: 0001725430
- company_name: INTELLIGENT BIO SOLUTIONS INC.
- filed_at: 2022-10-11T23:59:59+00:00
- event_type: m_and_a
- sentiment: positive
- materiality_score: 0.85
- calibrated_materiality_score: 0.85
- confidence: high
- sec_items: 1.01, 2.01, 2.03, 3.02, 3.03, 5.02, 5.03, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1725430/000149315222028015/0001493152-22-028015-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1725430/000149315222028015/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001493152-22-028015
- JSON: https://secwatch.observer/filing/0001493152-22-028015.json
- Plain text: https://secwatch.observer/filing/0001493152-22-028015.txt

## Key facts
- Executive change
  Jason Isenberg was appointed as Director at INTELLIGENT BIO SOLUTIONS INC..
  - Action: appointed
  - Role: Director
  source text: each of Jason Isenberg and David Jenkins, each being designee of the Investors under the Investors’ Rights Agreement, was appointed as a member of the Board.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1725430/000149315222028015/0001493152-22-028015-index.htm
- Executive change
  David Jenkins was appointed as Director at INTELLIGENT BIO SOLUTIONS INC..
  - Action: appointed
  - Role: Director
  source text: each of Jason Isenberg and David Jenkins, each being designee of the Investors under the Investors’ Rights Agreement, was appointed as a member of the Board.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1725430/000149315222028015/0001493152-22-028015-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.